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Adenoviruses for gene or oncolytic therapy are under development. Notable among these strategies is
adenoviral delivery of the tumor suppressor p53. Since all therapeutics have limitations in certain
settings, we have undertaken retroviral suppressor screens to identify genes conferring resistance to
adenovirus-delivered p53. These studies identified the tumor antigen LRRC15, which is frequently over-
expressed in multiple tumor types, as a repressor of cell death due to adenoviral p53. LRRC15, however,
does not impede p53 function per se but impedes adenoviral infection. Specifically, LRRC15 causes
redistribution of the coxsackievirus-adenovirus receptor away from the cell surface. This effect is mani-
fested in less adenoviral binding to the surfaces of LRRC15-expressing cells. This discovery, therefore, not
only is important for understanding adenoviral biology but also has potentially important implications for
adenovirus-based anticancer therapeutics.
Adenoviral vectors have been developed as agents for
either intratumoral or systemic gene or oncolytic therapy (6,
13). One approach has been the development of adenoviral
vectors that carry the tumor suppressor p53 (15). p53 is the
most frequently mutated gene in human cancer (22). When
activated, or delivered virally, p53 can bring about two ma-
jor phenotypic effects, growth arrest or apoptosis (4). Many
tumor cells have a higher predisposition to die in response
to p53 than their normal counterparts, making delivery of
p53 a selective way to induce tumor cell death. However, as
with all therapeutic strategies, not all agents will work
equally well in all tumor settings. Differences in genetic
backgrounds and gene expression profiles in tumors, differ-
ences in the tissues of origin of the tumor, and differences
between individuals can render the use of any particular
therapeutic strategy ineffective. For example, the use of
adenovirus-delivered p53 in many sarcomas that overexpress
the p53 negative regulator Mdm2 (12), which causes degra-
dation of p53 (7, 8), appears to be limited. The identification
of high levels of Mdm2 in tumors, however, not only points
to informed selective use of adenovirus-delivered p53 but
also suggests the development of combination therapies in-
volving adenoviral p53 together with agents that perturb the
negative regulation of p53 by Mdm2.
Many other tumor types that retain wild-type p53 are con-
sidered to contain mutational events, in addition to overex-
pression of Mdm2, that in some way impede p53 function. We
set out, therefore, to search for such factors using genome-
wide retroviral insertional mutagenesis screens. We considered
that retrovirus-infected cell clones that were resistant to the
death-inducing action of adenovirus-delivered p53 would con-
tain retroviral insertions that affected either p53 function per
se, cell death pathways downstream of p53, or the effective
gene delivery or expression of p53 from the viral vector. Genes
identified by this approach, like mdm2, would not only be
useful indicators for the selective use of adenovirus-delivered
p53 but may also represent potential novel targets for combi-
nation therapy.
MATERIALS AND METHODS
Plasmids. Plasmids involved in the generation of ERM (enhanced retroviral
mutagenesis) virus-infected cells were kindly provided by Zhou Songyang (Bay-
lor College of Medicine, Houston, TX) and have been described previously (9).
pWZLneo-EcoR and pcDNA3-LRRC15-hemagglutinin (HA) were kind gifts
from Gordon Peters (Cancer Research UK—London Research Institute) and
Daniel Haber (Harvard Medical School), respectively. pBabePuro-LRRC15-HA
was generated by digestion of pcDNA-LRRC15-HA with HindIII and BamHI.
The fragment was then blunt-ended and cloned into the SnaBI site of pBabe-
Puro. Expression vectors for p53 (pCB6p53) and Mdm2 (pCHDM21A) have
been described previously (3, 11). The green fluorescent protein (GFP) expres-
sion plasmid EGFP-N1 is from BD Biosciences.
Cell culture and generation of cell lines. Saos2-EcoR, A549-EcoR, and
HCT-116-EcoR cells were generated by amphotropic retroviral infection of
the respective parental cell lines with pWZLneo-EcoR as previously de-
scribed (16). The cells were then infected using an ecotropic packaging
system with either pBabePuro-LRRC15-HA or an empty pBabePuro vector
as a control. Saos2-ERM cells were generated as previously described (9). All
lines were maintained in Dulbecco’s modified Eagle’s medium supplemented
with 10% fetal bovine serum and incubated at 37°C under an atmosphere of
5% CO2 in air. Transgene expression was induced by addition of 1 g/ml
doxycycline (Dox) (Sigma). For p53 degradation assays, Saos2 cells were
transiently transfected by calcium phosphate precipitation as described else-
where (2). After 16 h, cells were washed and then incubated for a further 24 h
before harvesting for Western blotting.
Generation of replication-defective adenoviruses. Plasmid EGFP-N1-p53 was
made by inserting wild-type p53 sequences into the EcoRI and BamHI restriction
sites of pEGFP-N1 (Clontech). pShuttleCMV-GFP and pShuttleCMV-p53 were
made by inserting the GFP and WTp53-GFP fragments from plasmids EGFP-N1
and EGFP-N1p53 into pShuttleCMV (Stratagene) using BglII and NotI restric-
tion sites. Linearized “Shuttle” plasmids were electroporated into BJ5183-AD-1
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electrocompetent cells (Stratagene) containing the Adeasy-1 adenoviral con-
struct (Stratagene). Recombinant plasmids were then amplified in XL10-Gold
cells (Stratagene) and transfected into HEK293 cells after restriction digestion
with PacI. Following infectious adenovirus amplification in 293 cells, purified
virus was isolated by freeze-thaw extraction and titered using the BD Bioscience
Adeno-X Rapid Titer kit. Adenoviruses were added to cell cultures at the
multiplicities of infection indicated in the figures and legends.
Western blotting. Cells were lysed in a 2 Western sodium dodecyl sulfate
sample buffer and transferred to nitrocellulose membranes as previously de-
scribed (2). Membranes were probed using standard immunoblotting techniques
with antibodies that recognize LRRC15 (horseradish peroxidase-conjugated
HA; Roche), p53 (DO-1; Pharmingen), GFP (Covance), Hdm2 (Ab1; Oncogene
Science), the coxsackievirus-adenovirus receptor (CAR) (RmcB; ATCC), and
actin (clone 1A4; Sigma).
Flow cytometry and cell death assays. Total populations of cells, including
floating and adherent cells, were processed for flow cytometric analysis (FACScan;
Becton Dickinson) as described previously (17). Acquired events were analyzed
and quantified with CellQuest software (Becton Dickinson). The percentage of
cells with a sub-G1 DNA content was taken as a measure of the extent of
apoptosis in the cell population at that time.
Identification of ERM clones. Pools of cells infected with ERM viruses were
challenged with three rounds of infection with adenoviral p53. Each round of
infection was separated by a period of 7 to 10 days. RNA was isolated from
surviving clones and subjected to seminested reverse transcription-PCRs (RT-
PCRs) using the following primers and conditions. The RNAs were reverse
transcribed using a random primer, RT3 (5-GCAAATACGACTCACTATAG
GGATCCNNNNSTGG-3), and the GeneAmp RNA PCR core kit (Applied
Biosystems). Thirty cycles of PCR amplification were carried out using Proof-
Start polymerase (Qiagen) and PCR primers HA1 (5-CACCAAGGCGCGCC
AAGCACTATCCGTACGA-3) and T7 (5-GGCAAATACGACTCACTATA
GGG-3) according to the manufacturer’s manual. PCR conditions (MJ
Research DNA Engine PTC-200) were as follows: 95°C for 5 min; 30 cycles of
94°C for 30 s, 60°C for 1 min, and 72°C for 1 min; and finally 72°C for 10 min.
Products from these reactions were sequenced and integration sites identified
using the “Ensembl” genome browser (http://www.ensembl.org) and the NCBI
BLAST server (http://www.ncbi.nlm.nih.gov/BLAST).
qPCR. DNA and RNA were prepared using TRIzol reagent (Invitrogen).
Quantitative PCR (qPCR) analysis was carried using the DyNAmo Sybr green
2-step qRT-PCR kit (Finnzymes). Data were collected using a Chromo4 real-
time PCR detector and were analyzed with Opticon Monitor 3. Primers for
LRRC15 were as follows: forward, GCCTGTATGTACTGCTTTAACTC; re-
verse, GGATAATGCCATTTCAGTGGT. Primers for GFP were from Qiagen
(QT01171611). Primers for 18S rRNA have been described previously (5). qPCR
cycling parameters were 95°C for 15 min; 34 cycles of 94°C for 10 s, 55°C for 30 s,
and 72°C for 30 s; and 72°C for 10 min. Expression levels of genes analyzed by
qPCR were normalized relative to levels of 18S rRNA.
Analysis of CAR and integrin levels by flow cytometry. Cells at 80% con-
fluence were trypsinized or removed using phosphate-buffered saline (PBS)–
2.5 mM EDTA and pelleted at 1,200 rpm for 5 min. The pellet was washed
once with ice-cold fluorescence-activated cell sorter (FACS) buffer (PBS, 2%
fetal bovine serum, 0.5 mM EDTA [pH 8.0]). Cells were spun down, resus-
pended in ice-cold FACS buffer containing 5% fetal bovine serum and a
monoclonal antibody (2 g/ml), and incubated on ice for 60 min. Antibodies
against CAR (RmcB; ATCC), integrin v (ab16821; Abcam), integrin 3
(catalog no. 555752; BD Pharmingen), and integrin v5 (MAB2019Z;
Chemicon) were used. Cells were pelleted and washed three times with FACS
buffer. Cells were then resuspended in FACS buffer containing goat anti-
mouse immunoglobulin G conjugated with fluorescein isothiocyanate (cata-
log no. 0479; Dako) and incubated at room temperature for 30 min. Cells
were pelleted and again washed three times with FACS buffer, and the
expression of CAR or integrins on the cell surface was determined using a
Becton Dickinson FACSCalibur flow cytometer.
Immunofluorescence. Cells were seeded on glass coverslips at 50% confluence.
The following day, cells were infected with adenovirus (90 min on ice); washed
three times, for 5 min each time, with PBS; and fixed in PBS containing 4%
paraformaldehyde. For staining, coverslips were rinsed in PBS–0.1% Triton
X-100, incubated in blocking solution (PBS, 5% milk, 10% fetal bovine serum,
0.1% Triton X-100) for 30 min at room temperature, washed in blocking solution
without milk, and then incubated with an anti-adenovirus type 5 antibody
(ab6982; Abcam) for 60 min at 37°C. The coverslips were washed in PBS–0.1%
Triton X-100, incubated in a goat anti-rabbit secondary antibody conjugated with
Alexa Fluor 488 (A11008; Molecular Probes) for 30 min at 37°C, washed in
PBS–0.1% Triton X-100, and refixed in PBS–4% paraformaldehyde for 20 min at
room temperature. Cells were then washed again and mounted on slides. Mi-
croscopy was carried out using a Zeiss Axioplan 2IE microscope and ISIS
software.
RESULTS AND DISCUSSION
A screen for factors causing resistance to adenoviral p53
identifies LRRC15. In order to identify genes that cause resis-
tance to adenoviral p53, we utilized the ERM system, which
has been described previously (9, 10). In brief, this system
comprises tetracycline-responsive exon trap retroviruses (in
three reading frames) that integrate randomly throughout the
target cell genome when they are used to infect cells. Gene
fusions occur between exons of endogenous genes and a se-
quence tag on the retrovirus (ERM tag) via a splice donor site
in the viral vector. This causes up-regulation of expression of
the endogenous gene due to the enhancer effect of the viral
long terminal repeat (Fig. 1a). The ERM tag can then be used
to facilitate identification of the viral integration site by PCR.
Large pools of Saos2 cells, which are null for endogenous
p53, were infected with this viral system as previously described
(9, 16) in order to attain a high diversity of viral integration.
Pools of these cells were challenged with a regimen of infection
with adenoviral p53 that is just sufficient to kill an entire pop-
ulation of Saos2 cells without ERM (data not shown). Follow-
ing adenoviral infection of ERM cells, however, a number of
surviving colonies were found to emerge. Sequencing of one of
these clones using the viral tag as previously described (9)
revealed an in-frame integration at the beginning of exon 2 of
FIG. 1. A screen for suppressors of p53-induced cell death identi-
fied LRRC15. (a) Cells containing mutagenizing retroviruses were
generated and then challenged with adenoviral p53 as depicted. (b)
RT-PCR identified an in-frame viral integration at the beginning of
exon 2 of LRRC15. LTR, long terminal repeat; SD, splice donor site;
Tet-Off, tetracycline-responsive repressor element; UTR, untranslated
region.
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the LRRC15 gene (Fig. 1b). Since LRRC15 has a noncoding
first exon, this integration involved the entire reading frame of
LRRC15.
LRRC15 (also known as hLib) belongs to the leucine-rich
repeat superfamily, members of which are involved in cell-cell
and cell-extracellular matrix interactions. While it was first
identified as a protein induced by -amyloid (19), subsequent
studies have indicated that LRRC15 is frequently overex-
pressed in various tumor types and, in particular, is associated
with high-grade, aggressive breast and prostate tumors (14, 18,
20, 23). This association with tumor development caused us to
examine further the clones of cells with an integration in
LRRC15. First, we retested to determine whether the cells
were resistant to death by adenoviral p53 and, since expression
from ERM viruses is tetracycline responsive, whether resis-
tance to cell death was dependent on a viral integration. For
this purpose, cells were incubated with the tetracycline analog
Dox (1 g/ml for 48 h) to switch off ERM integrations (the
ERM constructs are “Tet-Off” regulated). This caused a
marked reduction in the levels of both ERM-tagged LRRC15
and total LRRC15 (Fig. 2a). Cells were then challenged with
adenoviral p53 and assessed for cell death induction after 48 h
by flow cytometry as previously described (17). This revealed
clearly that an ERM integration was causing resistance to the
effects of adenoviral p53. In the absence of Dox, the amount of
cell death from adenoviral p53 was similar to that in control
cells. Following Dox treatment, however, cell death from ad-
enoviral p53 was markedly increased (Fig. 2b). Interestingly,
this increase in cell death from adenoviral p53 when LRRC15
was switched off occurred concomitantly with an increase in
the levels of p53 protein (Fig. 2b).
Since the possibility remained that the ERM-LRRC15 cells
contained more than one viral integration, such that the effects
on cell death and p53 levels were independent of LRRC15, we
FIG. 2. LRRC15 impedes cell death due to adenoviral p53 and decreases p53 levels. (a) ERM-LRRC15 cells were treated with Dox for a period
of 48 h prior to infection with adenoviral p53, and the levels of ERM-tagged and total LRRC15 were determined by qPCR. (b) ERM-LRRC15
cells that had been treated with Dox for a period of 48 h were then, where indicated, infected with adenoviral p53 (Ad-p53) or a control “empty”
adenovirus (Ad-Cont). Cells were harvested for flow cytometry 48 h postinfection and for Western blotting 24 h postinfection. (c) Saos2 cells
were infected with a retrovirus expressing LRRC15 (Saos2-LRRC15) or an empty vector as a control (Saos2-Cont), and the presence of
HA-tagged LRRC15 was determined by Western blotting. (d) Saos2-LRRC15 cells and Saos2-Cont cells were infected with Ad-p53 or
Ad-Cont and analyzed after 48 h for cell death by flow cytometry and after 24 h for p53 expression by Western blotting. In cell death assays,
the percentage of cells with a sub-G1 DNA content was taken as a measure of the extent of apoptosis at the indicated time. NS, not
significant; P  0.12 by a two-tailed t test.
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reestablished a cell line that constitutively expresses LRRC15
from a heterologous promoter. Cells were infected with a ret-
roviral construct that had been generated using a cDNA for
LRRC15 that was previously described (14) (Fig. 2c). These
cells (Saos2-LRRC15) and empty vector control cells (Saos2-
pBabe) were infected with adenoviral p53 and analyzed for cell
death induction and p53 protein levels. As with the ERM-
LRRC15 cells in the absence of Dox, the presence of LRRC15
caused a marked reduction in the amount of cell death seen
following infection with adenoviral p53 (Fig. 2d), confirming
that the decreased level of cell death seen in ERM-LRRC15
cells is attributable to the viral integration in the LRRC15
locus. When the levels of p53 protein were analyzed follow-
ing adenoviral infection, the result was also similar to that
observed for ERM-LRRC15 cells: less p53 was detectable
in LRRC15-expressing cells than in vector-only controls
(Fig. 2d).
LRRC15 impedes adenoviral infection. The lower levels of
p53 in LRRC15-expressing cells caused us to consider whether
LRRC15 was impeding p53 function, in a manner similar to
that of Mdm2, by causing p53 degradation. To test this, Saos2
cells were transiently transfected as previously described (2)
with p53 in combination with either Mdm2, LRRC15, or an
empty vector as a control. In line with previous studies (7, 8),
coexpression of Mdm2 caused a marked reduction in p53 levels
(Fig. 3). In contrast, coexpression of LRRC15 had no effect on
p53 protein levels, indicating that LRRC15 does not promote
p53 degradation (Fig. 3).
Since we observed that expression of LRRC15 had no effect
on the levels or death-inducing activity of p53 following trans-
fection of cells by calcium phosphate precipitation (data not
shown), we next considered whether LRRC15 may affect either
the efficiency of infection or transgene expression by the ad-
enoviral vector. If either of these were possible, we would
expect to see similar effects on the expression of any adenovi-
rally delivered transgene. Saos2-LRRC15 cells, Saos2-pBabe
cells, and ERM-LRRC15 cells (with or without Dox) were
therefore infected with a previously described adenovirus con-
taining a transgene that expresses GFP (1). As was observed
with p53, GFP levels were indeed lower in Saos2-LRRC15
cells and ERM-LRRC15 cells than in Saos2-pBabe cells or
Dox-treated ERM-LRRC15 cells, respectively (the ERM-
driven integration of LRRC15 in these cells is “Tet-Off” and
hence is switched off by treatment with Dox) (Fig. 4a and b).
These results therefore indicate that LRRC15 impedes the
efficacy of adenoviral gene transfer per se, since the effects
we originally saw are not specific to p53. Since LRRC15 is a
plasma membrane protein, we considered it most likely that
LRRC15 impedes the infectivity of the adenoviral particle
as opposed to having an effect on, for example, transgene
expression. If the latter were the case, we would expect
fewer adenoviral genomes in LRRC15-expressing cells,
which would result in lower levels of transgene expression at
the protein level. As a reflection of the number of GFP-
containing adenoviral genomes in an infected cell popula-
tion, we analyzed GFP gene levels in adenovirus-infected
Saos2-LRRC15 cells, Saos2-pBabe cells, and ERM-
LRRC15 cells (with or without Dox) by qPCR as previously
described (5). This analysis indeed revealed that LRRC15-
expressing cells contain fewer copies of the GFP transgene
than control cells (Fig. 4c and d), and since the adenoviral
vectors used are replication defective, this finding confirms
that LRRC15 impedes adenoviral infection.
To test the generality of this observation, we extended our
study to two other cell lines from different tissues of origin—
HCT-116 and A549, which are derived from human colonic
and lung tumors, respectively. These cell lines were infected in
an identical manner to Saos2 cells with either a retrovirus
expressing LRRC15 or an empty viral vector as a control (Fig.
4e). In both cases, as was observed for Saos2 cells (Fig. 4a to
d), the presence of LRRC15 reduced both the amount of GFP
expressed in cells (Fig. 4f and g) and the number of GFP
transgenes upon transduction with adenovirus relative to those
observed for the controls (Fig. 4h and i).
LRRC15 affects surface CAR expression and cell surface
adenoviral binding. We were interested in understanding how
LRRC15 was affecting the delivery of adenovirus to cells. Since
changes in cellular morphology and cell cycle stage have been
reported to affect adenoviral infectivity (21), we first explored
whether LRRC15 was affecting either of these cellular pheno-
types, but no significant differences were observed between
cells expressing LRRC15 and those containing an empty viral
vector as a control (see Fig. S1 in the supplemental material).
A number of cell surface proteins have also been shown to
affect different stages of adenoviral infectivity. CAR is known
to mediate adenoviral attachment to the cell surface, while
integrins v3 and 35 control internalization (24). Since we
observed the most robust effects of LRRC15 expression in
A549 cells, we chose to use these cells to explore these cellular
parameters of adenoviral infection in the context of LRRC15.
Surface expression of integrins and CAR was therefore ana-
lyzed by flow cytometry in A549 cells expressing either
LRRC15 or an empty viral vector. This revealed that while the
expression of LRRC15 had limited effects on the surface ex-
pression of integrins v, 3, and 5, surface expression of CAR
was markedly reduced in cells expressing LRRC15 relative to
that in controls (Fig. 5a). Interestingly, total levels of CAR
were not affected by the expression of LRRC15 (Fig. 5b),
FIG. 3. LRRC15 does not affect p53 stability. Saos2 cells were
transiently transfected with the combinations of plasmids indicated.
After 24 h, cells were harvested and analyzed for protein expression by
Western blotting. Equal amounts of total protein were added to each
lane. The results shown are representative of five separate experi-
ments. GFP was included in each transfection as a control for trans-
fection efficiency.
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indicating that CAR must be redistributed away from the cell
surface in LRRC15-expressing cells. The destination(s) of the
relocalized CAR, however, has yet to be determined.
Since CAR is involved in the attachment of adenoviral par-
ticles to the cell surface, we postulated that LRRC15 may
directly affect this process. To test this, LRRC15-expressing
cells and controls were incubated on ice in order to permit
adenoviral attachment, but not internalization, such that at-
tachment could be assessed exclusively (24). Cells were then
incubated with the adenovirus that contains the GFP trans-
gene. Since the GFP is expressed only when the adenovirus is
within the host cells, cells were subsequently fixed and stained
with an antibody raised against whole adenovirus (type 5). This
clearly revealed, as would be predicted by the decrease in
FIG. 4. LRRC15 impedes adenoviral infection. (a and b) After 48 h of pretreatment with Dox (to switch off LRRC15, which is driven by the
ERM integration), ERM-LRRC15 cells were infected with an adenovirus containing a GFP transgene (Ad-GFP). Twenty-four hours postinfection,
GFP and GFP gene levels were determined by Western blotting (a) and qPCR (b), respectively. MOI, multiplicity of infection (number of virus
particles per cell as determined by plaque assay). (c and d) Saos2-LRRC15 cells and control (Saos2-Cont) cells were infected with an adenovirus
expressing GFP. Twenty-four hours postinfection, GFP and GFP gene levels were determined by Western blotting (c) and qPCR (d), respectively.
(e) HCT-116 and A549 cells were infected either with a retrovirus expressing HA-tagged LRRC15 or with an empty viral vector as a control. The
expression of HA-tagged LRRC15 was assessed and compared to that in Saos2-LRRC15 cells by Western blotting. (f and g) HCT-116-LRRC15
and HCT-116-Cont cells were infected with an adenovirus expressing GFP. Twenty-four hours postinfection, GFP and GFP gene levels were
determined by Western blotting (f) and qPCR (g), respectively. (h and i) A549-LRRC15 and A549-Cont cells were infected with an adenovirus
expressing GFP. Twenty-four hours postinfection, GFP and GFP gene levels were determined by Western blotting (h) and qPCR (i), respectively.
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surface CAR expression that we had observed, that LRRC15
markedly reduced the extent of attachment of adenoviral par-
ticles to the surfaces of cells (Fig. 6).
We believe that our findings, taken together with the fact
that LRRC15 is overexpressed in multiple tumor types, report
a new factor that not only is involved in the mediation of
adenoviral infectivity but also may have important implications
for the successful application of adenoviruses for either gene
therapy or oncolytic viral therapy. The further analysis of
LRRC15 in other cancers will undoubtedly determine how
far-reaching this effect of LRRC15 may be and whether it is a
factor for consideration in treating multiple tumor types. Iden-
tification of high levels of LRRC15 in a tumor could be used as
a criterion in decisions relating to the selective use, or the
strategy of administration, of an adenovirus-based therapy in
any individual case. Moreover, future studies to further explore
the mechanism of action of LRRC15 will also be rewarding
and may lead to strategies to enhance adenoviral infectivity in
cases where LRRC15 is either at normal levels or overex-
pressed.
FIG. 5. LRRC15 decreases cell surface, but not total, CAR levels.
(a) A549-LRRC15 and A549 control (Cont) cells were analyzed for
surface expression of the following parameters, which are known to
affect adenoviral transduction: CAR, integrin v, integrin 3, and in-
tegrin 5. Surface expression was quantified by flow cytometry, and the
percentage of cells showing a change in surface expression in A549-
LRRC15 cells is shown relative to that observed in A549-Cont cells.
(b) Total CAR levels in A549-LRRC15 and A549-Cont cells were
measured by Western blotting. A lysate from 293 cells is included as a
positive-control guideline for detection of CAR expression.
FIG. 6. LRRC15 impedes adenoviral attachment. (a and b) A549-LRRC15 (b) and A549 control (Cont) (a) cells were incubated with Ad-GFP
for 90 min on ice to permit adenoviral attachment but not internalization. Cells were subsequently stained with an anti-adenovirus type 5 (Ad5)
antibody and 4,6-diamidino-2-phenylindole (DAPI) before being visualized by fluorescent microscopy.
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